Global state: relapse medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE + ANY ANTIPSYCHOTIC may leads to lower global state: relapsemedium term (3‐12 months) Clinical diagnoses compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Mental state: no improvement medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: presence of first‐rank symptoms medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: extrapyramidal adverse effects Parkinsonism short term (< 3 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: extrapyramidal adverse effects Parkinsonismmedium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (change from baseline) in the medium term · patients with schizophrenia or related psychoses
1 finding from 1 review
Global state: relapse medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE + ANY ANTIPSYCHOTIC showed no clear difference in global state: relapse medium term (3‐12 months) compared with ANTIPSYCHOTIC + PLACEBO; GRADE not reported.
1 finding from 1 review
Mental state: no improvement medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: presence of first‐rank symptoms medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: extrapyramidal adverse effects Parkinsonism short term (< 3 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: extrapyramidal adverse effects Parkinsonism medium term (3‐12 months) Extrapyramidal Symptom Rating Scale (ESRS) · patients with schizophrenia or related psychoses
1 finding from 1 review
Quality of life (change from baseline) in the medium term · patients with schizophrenia or related psychoses
1 finding from 1 review
Global state: relapse ‐ medium term ‐ not measured · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: no improvement medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: presence of first‐rank symptoms medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) short term (< 3 months) Extrapyramidal Symptom Rating Scale (ESRS) · patients with schizophrenia or related psychoses
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (tremor) short term (< 3 months) Extrapyramidal Symptom Rating Scale (ESRS) · patients with schizophrenia or related psychoses
1 finding from 1 review
Quality of life (medium term: 12 months) · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: presence of first‐rank symptoms medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE showed no clear difference in mental state: presence of first‐rank symptoms medium term (3‐12… compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE showed no clear difference in adverse effects: extrapyramidal adverse effectsParkinsonism… compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review